الفهرس 
Review of LiteratureOnly 14 pages are availabe for public view
 |  | from | 93 |  |  |
| | | from | 93 | | |
Abstract
Type one ROP is considered as an emergency state to intervention within 48 h to prevent serious complications as retinal detachment and vision lost . In last decade improvement of neonatal care in Egypt increased saving more premature infants which lead to increased incidence of type one and type two ROP. Treatment modalities have been changed over last the decade in management. IVI of anti VEGF is now the first line of treatment in almost ophthalmology centers.
Thirteen patient developed ROP severe enough to require intervention. Five cases had stage 2 (38.50%), five cases had stage 3 (38.50%), and three cases APROP (23.10%). Zone 1 disease was found in 9 cases (69.3%), zone 2 was found in four cases (30.75%). The mean GA for type 1 ROP cases was 30,30 ± 1.8 weeks (28-35), mean birth weight was 1.3 ±0.3 (0,950-1.6), mean post menstrual age was 34 ±2.The mean follow-up time was 14± 1.37 months (range, 12-24 months) (table 8,9).
All of cases were regressed and plus disease displayed significant regression within 48-72 hours after treatment in all patients.
Efficacy of IVI of Ranibizumab in our study is 21 eyes (80,7%) of 26 completed vascularization of the temporal quadrant (zone III) in (21 eye ) (range 48 to 73 post menstrual weeks) on average.(figure 25-43)
Recurrence requiring treatment occurred in 5 eyes from 26 eyes (19.2%). Two cases (4 eyes) has done laser photocoagulation after formation of bilateral atrophic ridge in ant zone two at 75,81 post menstrual weeks. First case (31 GA) was examined at 35 PMA with severe APROP. The second case (29 GA) was examined at 31 PMA with stage 3 in zone 1.one eye (30 GA) was examined at 34 PMA with severe APROP has done Type one ROP is considered as an emergency state to intervention within 48 h to prevent serious complications as retinal detachment and vision lost . In last decade improvement of neonatal care in Egypt increased saving more premature infants which lead to increased incidence of type one and type two ROP. Treatment modalities have been changed over last the decade in management. IVI of anti VEGF is now the first line of treatment in almost ophthalmology centers.
Thirteen patient developed ROP severe enough to require intervention. Five cases had stage 2 (38.50%), five cases had stage 3 (38.50%), and three cases APROP (23.10%). Zone 1 disease was found in 9 cases (69.3%), zone 2 was found in four cases (30.75%). The mean GA for type 1 ROP cases was 30,30 ± 1.8 weeks (28-35), mean birth weight was 1.3 ±0.3 (0,950-1.6), mean post menstrual age was 34 ±2.The mean follow-up time was 14± 1.37 months (range, 12-24 months) (table 8,9).
All of cases were regressed and plus disease displayed significant regression within 48-72 hours after treatment in all patients.
Efficacy of IVI of Ranibizumab in our study is 21 eyes (80,7%) of 26 completed vascularization of the temporal quadrant (zone III) in (21 eye ) (range 48 to 73 post menstrual weeks) on average.(figure 25-43)
Recurrence requiring treatment occurred in 5 eyes from 26 eyes (19.2%). Two cases (4 eyes) has done laser photocoagulation after formation of bilateral atrophic ridge in ant zone two at 75,81 post menstrual weeks. First case (31 GA) was examined at 35 PMA with severe APROP. The second case (29 GA) was examined at 31 PMA with stage 3 in zone 1.one eye (30 GA) was examined at 34 PMA with severe APROP has done pars plana vitrectomy after regression two weeks after IVI.
All patients were monitored in the neonatal intensive care unit after treatment with close clinical observation. None of the patient was found to deteriorate during the early period. No serious ocular complications were observed including retinal detachment, cataract, endophthalmitis or intravitreal hemorrhage related to the injection procedure. Only subconjunctival hemorrhages limited to the injection site ( 8 eyes 30.7%).